All In Biotech

Drug Trial Radar · NCT05135546

Inhaled Recombinant Non-immunogenic Staphylokinase vs Placebo in Patients With COVID-19 - FORRIF Trial

Last checked: Nov 20, 2026Latest source record: Jul 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

4

Actual

Start

Dec 27, 2021

Primary completion

Feb 1, 2023

Study completion May 31, 2023

Sponsor

Lead sponsor
Supergene, LLCIndustry
Sponsor type
Industry
Collaborators
Russian Academy of Medical Sciences
First posted
Nov 26, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Objective: to evaluate the tolerability, safety and efficacy of inhaled usage of the Recombinant Non-immunogenic Staphylokinase (Fortelyzin®) vs placebo in patients with COVID-19.

Conditions

  • COVID-19

Interventions

  • Recombinant nonimmunogenic staphylokinaseDrug

    15 mg of drug reconstituted in 6 ml of 0.9% solution of NaCl for inhalation Other Name: Fortelyzin®

  • PlaceboDrug

    6 ml of 0.9% solution of NaCl for inhalation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of patients discharged from the hospital with clinical status according to the WHO Ordinal Scale For Clinical Improvement - 3 points or lessTime frame: 28 days post randomization

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • City Clinical Hospital No.52

    Moscow, Russia

  • N.V. Sklifosovsky Research Institute of Emergency Medicine

    Moscow, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.